TCR2 Therapeutics (TCRR) PT Lowered to $38 at BMO Capital, Following Strategic Business Update

October 20, 2021 4:29 PM EDT
Get Alerts TCRR Hot Sheet
Price: $2.89 -0.34%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 0 | New: 0
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

BMO Capital analyst Matthew Luchini lowered the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $38.00 (from $44.00) while maintaining a Outperform rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

BMO Capital